Compare Eli Lilly And Co (LLY) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Moody's Corporation — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Moody's Corporation trades at $464 (market cap $79.44B). The key difference: Eli Lilly And Co is far larger — about 13.1× Moody's Corporation's market cap, and Moody's Corporation pays the higher dividend (0.9%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Moody's Corporation for 132 Days on average.
| LLY | MCO | |
|---|---|---|
Market Cap | $1.04T | $79.44B |
Volume | 3,064,878 | 526,684 |
Sector | Health | Financials |
52-Week High | $1.28K | $539.61 |
52-Week Low | $799.57 | $412.23 |
Typical Hold Time | 93 Days | 132 Days |
Enterprise Value | $1.09T | $85.46B |
Dividend Yield | 0.59% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
MCO trades at $464.23, up 3.25% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 34.25% net margins and 80.15% ROE. Recent developments include a minority stake acquisition in PhilRatings and continued leadership in risk analytics, supported by 56% analyst buy ratings and a $536.40 consensus target.
Outlook remains positive given consistent revenue growth and expanding profitability, though technical resistance near $464 and high valuation multiples pose near-term risks. Long-term investors may find value in MCO's market position and dividend yield, but should monitor debt levels and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
